Wall Avenue Lunch: UnitedHealth Shares Wrestle Following Weak 2025 Outlook

Hear beneath or on the go on Apple Podcasts and Spotify

UnitedHealth’s recent ’25 outlook is available in beneath forecasts. (0:15) Novo Nordisk tumbles because it warns on weight problems drug gross sales. (1:31) Union Pacific and Northern Southern seal merger. (5:07)

That is an abridged transcript of the podcast:

Our high story to this point, UnitedHealth (UNH) shares proceed to battle after the corporate issued a recent outlook for 2025indicating income and adjusted earnings beneath Avenue forecasts amid a pointy improve in its medical bills.

The inventory, within the crimson at present, has misplaced greater than half its worth because it warned on the outlook in April and since confronted a sequence of detrimental headlines, together with the abrupt departure of its CEO and a probe into its Medicare enterprise.

With its Q2 outcomes, which missed on the underside line, the corporate projected EPS of $16 on $445.5 billion to $448 billion in income. Analysts have been on the lookout for EPS of $20.90 and income of $449.07 billion.

UNH attributed the price improve to medical value developments that sharply outweighed pricing developments and an ongoing affect of Medicare funding reductions.

New CEO Stephen Hemsley stated: “UnitedHealth Group has launched into a rigorous path again to being a high-performing firm totally serving the well being wants of people and society broadly.”

UNH reported $111.6 billion in income for the quarter, up about 13% yearly and in keeping with Avenue forecasts, thanks primarily to its insurance coverage unit, UnitedHealthcare, and Optum division.

In search of Alpha analyst YR Analysis stated, “it is now as much as administration to persuade traders that that is the ground and that the authorized and fraud allegations are insignificant.”

Additionally within the healthcare sector, Novo Nordisk (NVO) is tumbling after the Danish drugmaker lowered its full-year outlookciting, amongst different issues, strain on its weight problems drug franchise led by its GLP-1 treatment semaglutide.

On the similar time, the corporate named Maziar Mike Doustdar as its new president and chief govt officer, efficient Aug. 7, after the present CEO agreed to step down in Could. Doustdar is at the moment govt vice chairman of Worldwide Operations.

Eli Lilly (LLY), Novo’s major rival within the weight reduction drug market, and Hims & Hers Well being (Hims), which makes compounded variations of semaglutide, are additionally dealing with promoting.

With its H1 2025 outcomes, Novo Nordisk set its full-year development outlook for gross sales and working revenue at 8% – 14% and 10% – 16% on a currency-adjusted foundation, in comparison with 13% – 21% and 16% – 24% projected in Could.

The corporate cited decrease development expectations within the U.S. associated to Wegovy and Ozempic, the FDA-approved variations of semaglutide indicated for weight problems and diabetes.

And Merck (MRK) is chopping $3 billion from its annual bills because it prepares for generic competitors to its blockbuster most cancers drug, Keytruda.

The corporate issued an up to date outlook for full-year 2025, anticipating gross sales of $64.3 billion to $65.3 billion (prior: $64.1 billion to $65.6 billion) and adjusted EPS of $8.87 to $8.97 (prior: $8.82 to $8.97). Consensus is full-year EPS of $8.87 on income of $64.93 billion.

Amongst different lively shares, United Parcel Service (UPS) is underneath strain after the supply firm issued a blended Q2 earnings report. Income was 3.4% decrease than a 12 months in the past throughout the quarter to $21.2 billion and adjusted EPS got here in at $1.55 vs. $1.57 consensus and $1.79 a 12 months in the past.

UPS nonetheless didn’t present income or working revenue steering resulting from present macroeconomic uncertainty, however confirmed that it anticipates capital expenditures of about $3.5 billion and share repurchases of round $1 billion, which have been accomplished.

Procter & Gamble (PG) beat fiscal This fall earnings estimates. Natural gross sales elevated 2% to edge previous the consensus estimate of up 1.8%.

CEO Jon Moeller stated: “We grew gross sales and revenue in fiscal 2025 and returned excessive ranges of money to share homeowners in a dynamic, tough and risky setting.”

And PayPal (PYPL) stated bills rose greater than anticipated as money circulate declined. Complete working bills of $6.78 billion topped the Seen Alpha consensus of $6.24 billion, up from $6.26 billion in Q1.

However the firm boosted steering on the underside line for the total 12 months. It now expects 2025 non-GAAP EPS of $5.15-$5.30, in contrast with the $5.09 consensus and its earlier steering of $4.95-$5.10.

In different information of notice, U.S. smartphone shipments rose by 1% in Q2 as distributors front-loaded stock amid tariff issues. Samsung (OTCPK: SSNLF) noticed sturdy development, however Apple (AAPL) noticed a uncommon double-digit decline,

Analysis agency Canalys stated Samsung shipped 8.3 million items in Q2, a 38% year-over-year improve, boosting its market share to 31% from 23%.

Apple’s shipments dropped 11% to 13.3 million items, down from 14.9 million a 12 months earlier. Nonetheless, Apple retained the highest place with a 49% share of the U.S. market, forward of Samsung’s 31%.

Analysts at Canalys stated distributors proceed to front-load gadgets and keep excessive stock ranges to finest deal with the chance of tariffs. However simply 1% development total indicated tepid demand in an more and more pressured financial setting “and a widening hole between sell-in (to retailers) and sell-through (to clients).”

And Union Pacific (UNP) and Norfolk Southern (NSC) sealed their beforehand reported deal to create America’s first one-company transcontinental railroad.

The businesses stated they may seamlessly join over 50,000 route miles throughout 43 states from the East Coast to the West Coast, linking roughly 100 ports and almost each nook of North America. s.

Below the phrases of the settlement, Union Pacific will purchase Norfolk Southern in a inventory and money transaction, implying a price for Norfolk Southern of $320 per share based mostly on Union Pacific’s unaffected closing inventory value on July 16. The worth per share implies an enterprise worth of $85 billion, ensuing within the creation of a mixed enterprise of over $250 billion.

Editor’s Be aware: This text discusses a number of securities that don’t commerce on a significant U.S. trade. Please concentrate on the dangers related to these shares.